Patent 7973079 was granted and assigned to ReVision Therapeutics on July, 2011 by the United States Patent and Trademark Office.
Compounds that reduce serum retinol levels are used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods, compounds, and compositions to treat, for example, the macular degenerations and dystrophies or to alleviate symptoms associated with such ophthalmic conditions.